Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database
John F. Thompson(Melanoma Institute Australia), Vernon K. Sondak(Advanced Dermatology), Keith T. Flaherty(Cancer Research Center), Martín C. Mihm(Harvard University), Merrick I. Ross(Johns Hopkins University), Charles M. Balch(The University of Texas MD Anderson Cancer Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Stanley P. L. Leong(California Pacific Medical Center), T. M. Johnson(The University of Texas MD Anderson Cancer Center), Marcella M. Johnson(The University of Texas MD Anderson Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Kelly M. McMasters(University of Louisville), Donald L. Morton(University of California, Los Angeles), Natale Cascinelli, David R. Byrd(University of Washington), Seng-Jaw Soong(Johns Hopkins University), Alistair J. Cochran(Western Infirmary), Phyllis A. Gimotty(University of Pennsylvania), Shouluan Ding(Johns Hopkins University), Daniel G. Coit(Memorial Sloan Kettering Cancer Center)
Cited by 362
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k